NasdaqGS - Delayed Quote • USD
Dyne Therapeutics, Inc. (DYN)
At close: April 25 at 4:00 PM EDT
Pre-Market: 9:08 AM EDT
Key Executives
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Ms. Susanna Gatti High M.B.A. | Chief Operating Officer | 754.1k | -- | 1968 |
Dr. Jonathan McNeill M.D. | Chief Business Officer | 662.34k | -- | 1985 |
Mr. John G. Cox M.B.A. | CEO, President & Director | -- | -- | 1963 |
Dr. Romesh Subramanian Ph.D. | Co-Founder & Advisor | 565.17k | -- | 1965 |
Mr. Richard William Scalzo M.B.A. | Senior VP and Head of Finance & Administration | -- | -- | 1986 |
Mr. John Najim M.B.A. | Chief Technical Officer | -- | -- | -- |
Dr. Oxana Beskrovnaya Ph.D. | Chief Scientific Officer | 631.08k | -- | 1961 |
Ms. Amy Reilly | Senior VP and Head of Corporate Communications & Investor Relations | -- | -- | 1974 |
Mr. Daniel Wilson | Senior VP & Head of Legal | -- | -- | 1972 |
Ms. Kate Mitchell | VP & Head of Human Resources | -- | -- | -- |
Dyne Therapeutics, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 141
Description
Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.
Corporate Governance
Dyne Therapeutics, Inc.’s ISS Governance QualityScore as of April 1, 2024 is 9. The pillar scores are Audit: 7; Board: 7; Shareholder Rights: 8; Compensation: 10.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Recent Events
- Apr 05, 2024DEFA14A: Proxy StatementsSee Full Filing
- Mar 25, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Mar 05, 2024S-8: Offering RegistrationsSee Full Filing
- Jan 29, 2024SC 13G: Tender Offer/Acquisition ReportsSee Full Filing
- Jan 04, 20248-K: Corporate Changes & Voting MattersSee Full Filing
Upcoming Events
May 09, 2024 - May 13, 2024
Dyne Therapeutics, Inc. Earnings Call
Related Tickers
RNA Avidity Biosciences, Inc.
23.83
-5.02%
RVMD Revolution Medicines, Inc.
35.33
-0.73%
MOR MorphoSys AG
18.13
+0.44%
EWTX Edgewise Therapeutics, Inc.
15.94
-1.06%
KYMR Kymera Therapeutics, Inc.
33.35
-5.28%
JANX Janux Therapeutics, Inc.
47.10
-2.30%
VERA Vera Therapeutics, Inc.
38.69
-3.15%
CGON CG Oncology, Inc.
36.20
+0.42%
APGE Apogee Therapeutics, Inc.
45.86
-1.46%
MLTX MoonLake Immunotherapeutics
42.25
-0.42%